Alpha-1 Antitrypsin Deficiency Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Apic Bio, Dicerna Pharma, Peak Bio, Arrowhead Pharma

“Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alpha-1 Antitrypsin Deficiency Market. 

The Alpha-1 Antitrypsin Deficiency Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Alpha-1 Antitrypsin Deficiency Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Alpha-1 Antitrypsin Deficiency treatment therapies with a considerable amount of success over the years. Alpha-1 Antitrypsin Deficiency Key players such as – Apic Bio, Dicerna Pharmaceuticals, Peak Bio, Arrowhead Pharmaceuticals, and others, are developing therapies for the Alpha-1 Antitrypsin Deficiency treatment 

• Alpha-1 Antitrypsin Deficiency Emerging therapies such as – APB-101, Belcesiran, PHP 303, ARO-AAT, and others are expected to have a significant impact on the Alpha-1 Antitrypsin Deficiency market in the coming years.  

• In April 2024, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company dedicated to harnessing the potential of RNA medicines to transform human health, today announced the approval of its first clinical trial application (CTA) for the RestorAATion-2 trial of WVE-006. This is the company’s first-in-class RNA editing oligonucleotide, being developed to treat alpha-1 antitrypsin deficiency (AATD). WVE-006 is GalNAc-conjugated and administered subcutaneously, without the use of a lipid nanoparticle (LNP) delivery system.

• In April 2024, Enlivex Therapeutics has announced promising topline safety and efficacy results from its Phase II clinical trial of Allocetra, an off-the-shelf cell therapy for sepsis. The randomized, placebo-controlled trial aims to identify the optimal dose of Allocetra when administered in conjunction with the standard care for sepsis caused by different infections.

• In July 2023, Grifols successfully achieved the enrollment goal of 339 participants for the Phase III trial known as the Study of ProlAstin-c Randomized Therapy with Alpha-1 augmentation (SPARTA), which aims to address emphysema. This placebo-controlled, double-blind, randomized study is structured to evaluate the safety and effectiveness of two doses of Alpha1-Proteinase inhibitor Prolastin-C—60mg/kg and 120mg/kg—administered once weekly in comparison to a placebo. The primary objective is to assess whether these doses can slow down the progression of lung tissue loss in patients with emphysema.

Alpha-1 Antitrypsin Deficiency Overview

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by a deficiency or malfunction of alpha-1 antitrypsin (AAT) protein, which is produced primarily in the liver. AAT is important for protecting the lungs from damage caused by enzymes produced by white blood cells, specifically neutrophil elastase.

Get a Free sample for the Alpha-1 Antitrypsin Deficiency Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight

Route of Administration

Alpha-1 Antitrypsin Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide

• Peptide

• Small molecule

Alpha-1 Antitrypsin Deficiency Pipeline Therapeutics Assessment

• Alpha-1 Antitrypsin Deficiency Assessment by Product Type

• Alpha-1 Antitrypsin Deficiency By Stage and Product Type

• Alpha-1 Antitrypsin Deficiency Assessment by Route of Administration

• Alpha-1 Antitrypsin Deficiency By Stage and Route of Administration

• Alpha-1 Antitrypsin Deficiency Assessment by Molecule Type

• Alpha-1 Antitrypsin Deficiency by Stage and Molecule Type

DelveInsight’s Alpha-1 Antitrypsin Deficiency Report covers around 4+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Alpha-1 Antitrypsin Deficiency product details are provided in the report. Download the Alpha-1 Antitrypsin Deficiency pipeline report to learn more about the emerging Alpha-1 Antitrypsin Deficiency therapies

Emerging Alpha-1 Antitrypsin Deficiency Drugs Under Different Phases of Clinical Development Include:

• APB-101: Apic Bio

• Belcesiran: Dicerna Pharmaceuticals

• PHP 303: Peak Bio

• ARO-AAT: Arrowhead Pharmaceuticals 

Alpha-1 Antitrypsin Deficiency Pipeline Analysis:

The Alpha-1 Antitrypsin Deficiency pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Alpha-1 Antitrypsin Deficiency treatment with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alpha-1 Antitrypsin Deficiency Treatment.

• Alpha-1 Antitrypsin Deficiency key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Alpha-1 Antitrypsin Deficiency Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alpha-1 Antitrypsin Deficiency market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Alpha-1 Antitrypsin Deficiency drugs and therapies

Alpha-1 Antitrypsin Deficiency Pipeline Market Drivers

• Increasing investment in the R&D activities for developing novel therapeutics

• Rise in awareness among people

Alpha-1 Antitrypsin Deficiency Pipeline Market Barriers

• Lack of diagnostic methods

• Treatment dosage being poorly standardized

Scope of Alpha-1 Antitrypsin Deficiency Pipeline Drug Insight    

• Coverage: Global

• Key Alpha-1 Antitrypsin Deficiency Companies: Apic Bio, Dicerna Pharmaceuticals, Peak Bio, Arrowhead Pharmaceuticals, and others

• Key Alpha-1 Antitrypsin Deficiency Therapies: APB-101, Belcesiran, PHP 303, ARO-AAT, and others

• Alpha-1 Antitrypsin Deficiency Therapeutic Assessment: Alpha-1 Antitrypsin Deficiency current marketed and Alpha-1 Antitrypsin Deficiency emerging therapies

• Alpha-1 Antitrypsin Deficiency Market Dynamics:  Alpha-1 Antitrypsin Deficiency market drivers and Alpha-1 Antitrypsin Deficiency market barriers 

Request for Sample PDF Report for Alpha-1 Antitrypsin Deficiency Pipeline Assessment and clinical trials

Table of Contents

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/